These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18045057)

  • 1. Bruton's tyrosine kinase as a new therapeutic target.
    Uckun FM; Tibbles HE; Vassilev AO
    Anticancer Agents Med Chem; 2007 Nov; 7(6):624-32. PubMed ID: 18045057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical potential of targeting Bruton's tyrosine kinase.
    Uckun FM
    Int Rev Immunol; 2008; 27(1-2):43-69. PubMed ID: 18300055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide].
    Mahajan S; Ghosh S; Sudbeck EA; Zheng Y; Downs S; Hupke M; Uckun FM
    J Biol Chem; 1999 Apr; 274(14):9587-99. PubMed ID: 10092645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism.
    Uckun FM; Vassilev A; Bartell S; Zheng Y; Mahajan S; Tibbles HE
    Leuk Lymphoma; 2003 Sep; 44(9):1569-77. PubMed ID: 14565661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors.
    Uckun F; Dibirdik I; Sarkissian A; Qazi S
    Arzneimittelforschung; 2011; 61(4):252-9. PubMed ID: 21650085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase.
    Uckun FM; Zheng Y; Cetkovic-Cvrlje M; Vassilev A; Lisowski E; Waurzyniak B; Chen H; Carpenter R; Chen CL
    Clin Cancer Res; 2002 May; 8(5):1224-33. PubMed ID: 12006542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-cyano-N-(2,5-dibromophenyl)-beta-hydroxybut-2-enamide.
    Ghosh S; Uckun FM
    Acta Crystallogr C; 1999 Aug; 55 ( Pt 8)():1364-5. PubMed ID: 10483706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dual function anti-leukemic agent with anti-thrombotic activity.
    Tibbles H; Vassilev A; Uckun FM
    Leuk Lymphoma; 2002 May; 43(5):1121-7. PubMed ID: 12148895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model.
    Cetkovic-Cvrlje M; Uckun FM
    Br J Haematol; 2004 Sep; 126(6):821-7. PubMed ID: 15352986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity.
    van den Akker E; van Dijk TB; Schmidt U; Felida L; Beug H; Löwenberg B; von Lindern M
    Biol Chem; 2004 May; 385(5):409-13. PubMed ID: 15196000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical toxicity and pharmacokinetics of the Bruton's tyrosine kinase-targeting anti-leukemic drug candidate, alpha-cyano-beta-hydroxy-beta-methyl-N- (2,5-dibromophenyl) propenamide (LFM-A13).
    Uckun FM; Tibbles H; Venkatachalam T; DuMez D; Erbeck D
    Arzneimittelforschung; 2007; 57(1):31-46. PubMed ID: 17341007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.
    Bam R; Ling W; Khan S; Pennisi A; Venkateshaiah SU; Li X; van Rhee F; Usmani S; Barlogie B; Shaughnessy J; Epstein J; Yaccoby S
    Am J Hematol; 2013 Jun; 88(6):463-71. PubMed ID: 23456977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Bruton's tyrosine kinase inhibitors in HIV-1-infected cells.
    Guendel I; Iordanskiy S; Sampey GC; Van Duyne R; Calvert V; Petricoin E; Saifuddin M; Kehn-Hall K; Kashanchi F
    J Neurovirol; 2015 Jun; 21(3):257-75. PubMed ID: 25672887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA).
    Heinonen JE; Smith CI; Nore BF
    FEBS Lett; 2002 Sep; 527(1-3):274-8. PubMed ID: 12220673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer.
    Tankiewicz-Kwedlo A; Hermanowicz JM; Domaniewski T; Pawlak K; Rusak M; Pryczynicz A; Surazynski A; Kaminski T; Kazberuk A; Pawlak D
    Br J Pharmacol; 2018 Mar; 175(5):743-762. PubMed ID: 29160911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer.
    Rozkiewicz D; Hermanowicz JM; Tankiewicz-Kwedlo A; Sieklucka B; Pawlak K; Czarnomysy R; Bielawski K; Surazynski A; Kalafut J; Przybyszewska A; Koda M; Jakubowska K; Rivero-Muller A; Pawlak D
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1697-1711. PubMed ID: 32912025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2).
    Liu Q; Batt DG; Lippy JS; Surti N; Tebben AJ; Muckelbauer JK; Chen L; An Y; Chang C; Pokross M; Yang Z; Wang H; Burke JR; Carter PH; Tino JA
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4265-9. PubMed ID: 26320619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bruton's tyrosine kinase as a drug discovery target.
    Pan Z
    Drug News Perspect; 2008 Sep; 21(7):357-62. PubMed ID: 19259548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bruton's tyrosine kinase drives neuroinflammation and anxiogenic behavior in mouse models of stress.
    Ghosh S; Mohammed Z; Singh I
    J Neuroinflammation; 2021 Dec; 18(1):289. PubMed ID: 34895246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils. II. Effects of LFM-A13, a specific Btk inhibitor.
    Gilbert C; Levasseur S; Desaulniers P; Dusseault AA; Thibault N; Bourgoin SG; Naccache PH
    J Immunol; 2003 May; 170(10):5235-43. PubMed ID: 12734372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.